Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
976 stopped studies mapped to Digestive System Carcinoma and descendants · 93% state a reason
Over the 976 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04632199 | Study to Assess the Safety and Efficacy of Intravenous Injection of the Imaging Agent… | Phase 1 | withdrawn | Nov 17, 2020 | Ipsen | Business decision not related to any safety or tolerability concern | Safety / toxicity |
| NCT03998033 | Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma(ET-109) | Phase 1 | terminated | Jun 25, 2019 | Eureka Therapeutics Inc. | Reallocation of resources to new HCC study. | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT01525069 | Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic… | Phase 1 | terminated | Feb 2, 2012 | Washington University School of Medicine | Equipment that was used in the study was discontinued | Other (stated, no rule matched) |
| NCT04775056 | A Study to Evaluate Vaccines Against COVID-19 in the Real World | — | withdrawn | Mar 1, 2021 | Humanity & Health Medical Group Limited | No sponsor | Other (stated, no rule matched) |
| NCT02446925 | Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study | N/A | terminated | May 18, 2015 | Wright State University | Insufficient number of subjects meeting inclusion criteria | Other (stated, no rule matched) |
| NCT02575339 | MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | terminated | Oct 14, 2015 | Kathy Miller | Funder Decision | Other (stated, no rule matched) |
| NCT00746590 | Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma | Phase 2 | terminated | Sep 4, 2008 | BTG International Inc. | Study terminated prematurely by sponsor for business reason. One patient was enrolled. | Enrollment / accrual |
| NCT04306861 | Novel MRI Techniques for Pancreatic Cancer | — | withdrawn | Mar 13, 2020 | Beth Israel Deaconess Medical Center | Enrollment and other trial activities have temporarily paused due to COVID-19 and are expected to… | COVID-19 / pandemic |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04717687 | Pilot Study on the Evaluation of Irreversible Electroporation Technique in Infiltrating…(HOPE) | N/A | withdrawn | Jan 22, 2021 | Poitiers University Hospital | No enrollment | Enrollment / accrual |
| NCT03402607 | Trial Comparing PLA to HIGRT (PROVE-HCC)(PROVE-HCC) | N/A | terminated | Jan 18, 2018 | Duke University | Lack of enrollment | Enrollment / accrual |
| NCT03012282 | CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer | N/A | terminated | Jan 6, 2017 | University of Washington | Termination due to slow accrual | Enrollment / accrual |
| NCT03634683 | A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Lion TCR Pte. Ltd. | Major changes in manufacturing process and investigational product | Drug supply |
| NCT04895046 | Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Phase 2 | withdrawn | May 20, 2021 | Walid Shaib, MD | Funder decision | Other (stated, no rule matched) |
| NCT01402908 | A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC…(PATRON) | Phase 3 | terminated | Jul 26, 2011 | Cellxpert Biotechnology Corp. | Due to Interim Analysis and business concerns | Efficacy / futility |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in… | Phase 2 | terminated | Dec 13, 2007 | Boston Scientific Corporation | OncoGel did not show any impact on overall tumor response | Other (stated, no rule matched) |
| NCT03956940 | Analysis of cfDNA in Patients With Hepatocarcinoma and Treated by Sorafenib or Regorafenib(HELP) | N/A | terminated | May 21, 2019 | Institut du Cancer de Montpellier - Val d'Aurelle | Change of the scientific and medical context that is no longer favorable to our study. This has… | Other (stated, no rule matched) |
| NCT01371240 | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving… | Early Phase 1 | withdrawn | Jun 10, 2011 | University Hospitals Cleveland Medical Center | Study never started | Other (stated, no rule matched) |
| NCT04546828 | A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy… | Phase 2 | withdrawn | Sep 14, 2020 | Samsung Medical Center | problem of sponsor | Other (stated, no rule matched) |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04190498 | Sleep Apnoea Syndrome and Hepatocellular Carcinoma(ECHAPS) | — | withdrawn | Dec 9, 2019 | University Hospital, Grenoble | the possibility of obtaining histological data is too low due to the lack of availability of… | Other (stated, no rule matched) |
| NCT04727541 | Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer(NEOBIL) | Phase 2 | terminated | Jan 27, 2021 | AIO-Studien-gGmbH | Based on results of another phase II study with bintrafusp alfa in combination with gemcitabine… | Enrollment / accrual |
| NCT03059147 | Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced… | Phase 1 | terminated | Feb 23, 2017 | SignalRX Pharmaceuticals, Inc. | Lack of recruitment and sponsor's priority changes | Enrollment / accrual |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Apollomics (Australia) Pty. Ltd. | Study terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT04465734 | A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04… | Phase 3 | withdrawn | Jul 10, 2020 | Shanghai Henlius Biotech | The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been… | Other (stated, no rule matched) |
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | Phase 1 / Phase 2 | terminated | Oct 20, 2017 | Genoscience Pharma | only phase 1b was completed and the phase 2 will be an another study, finally | Other (stated, no rule matched) |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | Phase 2 | withdrawn | Aug 1, 2016 | Wake Forest University Health Sciences | no accrual rate | Enrollment / accrual |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | Phase 2 | withdrawn | Nov 12, 2020 | Qilu Hospital of Shandong University | insufficient money | Other (stated, no rule matched) |
| NCT02102022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on… | Phase 1 / Phase 2 | terminated | Apr 2, 2014 | Polaris Group | not stated | Not stated |
| NCT02704130 | TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma | N/A | terminated | Mar 9, 2016 | Wake Forest University Health Sciences | Lack of funding | Funding |
| NCT04480190 | Neoadjuvant Therapy in Biliary Adenocarcinoma | Phase 1 | withdrawn | Jul 21, 2020 | Jordan Kharofa | Difficulty accruing | Enrollment / accrual |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With… | Phase 1 / Phase 2 | terminated | Oct 16, 2018 | Elevar Therapeutics | Terminated after completion of Part 1 due to a change in research plan. | Other (stated, no rule matched) |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases… | Phase 1 | withdrawn | Sep 25, 2018 | Sorrento Therapeutics, Inc. | Unable to enroll subjects | Enrollment / accrual |
| NCT03852836 | Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images(BiliFast) | N/A | terminated | Feb 25, 2019 | IHU Strasbourg | COVID Pandemy - recruitment issue | COVID-19 / pandemic |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment… | Phase 2 | withdrawn | Aug 25, 2021 | Fudan University | Repeat registration | Other (stated, no rule matched) |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Sep 11, 2017 | NYU Langone Health | The study was stopped earlier than anticipated due to slow accrual | Enrollment / accrual |
| NCT04231929 | BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre…(BIOPEARL-FIRST) | N/A | withdrawn | Jan 18, 2020 | Terumo Europe N.V. | Study cancelled by Sponsor decision | Sponsor / business decision |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT03979547 | EXALT: EXercise Attenuates Liver Tumors Trial(EXALT) | N/A | terminated | Jun 7, 2019 | Milton S. Hershey Medical Center | Recruitment challenges | Enrollment / accrual |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III… | Phase 2 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Safety concerns | Safety / toxicity |
| NCT03784417 | EUS-guided Laser Ablation in Pancreatic Adenocarcinoma | N/A | terminated | Dec 21, 2018 | Catholic University of the Sacred Heart | device unavalaible | Other (stated, no rule matched) |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | Phase 2 | terminated | Dec 1, 2020 | American University of Beirut Medical Center | pharma company decision to withdraw the financial and IMP support | Funding |
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid… | Phase 1 / Phase 2 | terminated | Mar 14, 2019 | Calithera Biosciences, Inc | Slow Enrollment | Enrollment / accrual |
| NCT02982720 | Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab… | Phase 2 | terminated | Dec 5, 2016 | Aiwu Ruth He, MD | Manufacturer discontinued Sylatron | Drug supply |
| NCT03472833 | High-dose Vitamin D3 in Pancreas Cancer(VITdCUT) | Phase 3 | terminated | Mar 21, 2018 | Medical University of Graz | slow recruitment, patients lost to follow-up due to Covid-19 pandemic. | COVID-19 / pandemic |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | Phase 1 | suspended | Aug 10, 2020 | Beijing Tsinghua Chang Gung Hospital | Adjust the plan | Other (stated, no rule matched) |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable… | Phase 2 | withdrawn | Oct 8, 2019 | Roswell Park Cancer Institute | implementation issues | Other (stated, no rule matched) |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | withdrawn | Jan 6, 2022 | Flame Biosciences | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 24, 2022source: clinicaltrials